This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders, Other  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic

Kevin Cooper, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The National Eczema Association for Science and Education (NEASE) is the representative and the advocate for 20 million people in the United States who have eczema problems, and I write on their behalf. Our major concern is the well-being of the patients we represent. The detailed comments by Stern¹ on the decision-making process used by the external pediatric committee in advising the US Food and Drug Administration (FDA) regarding topical calcineurin inhibitors raise several issues that are useful to place into public discussion.

The NEASE receives donations for various programs from many individual and corporate donors in the 3 segments of our mission: support, awareness, and research. All decisions by the NEASE are made without the participation of donors, and the NEASE has a very strict corporate relations policy.

The NEASE scientific advisory committee and board of directors considered it important to seek an unbiased assessment of . . . [Full Text of this Article]

AUTHOR INFORMATION